Highlight
Recent research validates the Anti-BNLF2b (P85-Ab) antibody as a highly sensitive and specific biomarker for early detection of nasopharyngeal carcinoma (NPC). The novel P85-Ab assay outperforms the traditional Epstein-Barr virus IgA antibody score and exhibits comparable performance to circulating EBV DNA testing. Its robust accuracy across demographic subgroups supports its potential for broad population-based NPC screening.
